{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:28:48Z","timestamp":1793975328550,"version":"4.8.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bbrep.2026.102814","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:17:41Z","timestamp":1790331461000},"page":"102814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Membrane-associated HDAC11: A potential new therapeutic targeting compartment in cancer cells"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7065-1185","authenticated-orcid":false,"given":"Payel","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bbrep.2026.102814_bib1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): Evolution, specificity, role in transcriptional complexes, and pharmacological actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes"},{"issue":"6","key":"10.1016\/j.bbrep.2026.102814_bib2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbrep.2026.102814_bib3","doi-asserted-by":"crossref","DOI":"10.2174\/0115734064378681251128061500","article-title":"Design and synthesis of piperidine hydroxamate scaffolds as novel HDAC inhibitors with apoptotic potential in human cervical cancer cells","author":"Kiruthiga","year":"2026","journal-title":"Med. Chem."},{"issue":"2","key":"10.1016\/j.bbrep.2026.102814_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.9","article-title":"HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses","volume":"4","author":"Bolden","year":"2013","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.bbrep.2026.102814_bib5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/17501911.2026.2667351","article-title":"Epigenetic mechanisms and therapeutic targeting across diverse malignancies","volume":"18","author":"Harihar","year":"2026","journal-title":"Epigenomics"},{"key":"10.1016\/j.bbrep.2026.102814_bib6","article-title":"HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway","volume":"17","author":"Gu","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrep.2026.102814_bib7","article-title":"Mechanisms of HDACs in cancer development","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bbrep.2026.102814_bib8","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/cancers13040634","article-title":"Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives","volume":"13","author":"Jenke","year":"2021","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.bbrep.2026.102814_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015066","article-title":"The roles of histone deacetylases in the regulation of ovarian cancer metastasis","volume":"24","author":"Xu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bbrep.2026.102814_bib10","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1111\/febs.15895","article-title":"HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes","volume":"289","author":"N\u00fa\u00f1ez-\u00c1lvarez","year":"2022","journal-title":"FEBS J."},{"issue":"7","key":"10.1016\/j.bbrep.2026.102814_bib11","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.chembiol.2018.04.007","article-title":"Histone deacetylase 11 is an \u03b5-N-Myristoyllysine hydrolase","volume":"25","author":"Moreno-Yruela","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"3","key":"10.1016\/j.bbrep.2026.102814_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/acschembio.7b00942","article-title":"Histone deacetylase 11 is a fatty-acid deacylase","volume":"13","author":"Kutil","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbrep.2026.102814_bib13","article-title":"shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrep.2026.102814_bib14","article-title":"HDAC11: a novel target for improved cancer therapy","volume":"166","author":"Liu","year":"2023","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.bbrep.2026.102814_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116634","article-title":"Biological function and small molecule inhibitors of histone deacetylase 11","volume":"276","author":"Jia","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrep.2026.102814_bib16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102814_bib17","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1038\/s41598-020-61295-6","article-title":"Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2","volume":"10","author":"Bora-Singhal","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bbrep.2026.102814_bib18","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.7150\/jca.66914","article-title":"Histone deacetylase (HDAC) 11 inhibits matrix metalloproteinase (MMP) 3 expression to suppress colorectal cancer metastasis","volume":"13","author":"Wen","year":"2022","journal-title":"J. Cancer"},{"issue":"8","key":"10.1016\/j.bbrep.2026.102814_bib19","doi-asserted-by":"crossref","first-page":"8124","DOI":"10.1021\/acs.jmedchem.4c02550","article-title":"HDAC11 inhibition as a potential therapeutic strategy for AML: target identification, lead discovery, antitumor potency, and mechanism investigation","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bbrep.2026.102814_bib20","first-page":"172","article-title":"HDAC11 is related to breast cancer prognosis and inhibits invasion and proliferation of breast cancer cells","volume":"16","author":"Zhao","year":"2023","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102814_bib21","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1038\/s41467-019-12222-5","article-title":"Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes","volume":"10","author":"Leslie","year":"2019","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bbrep.2026.102814_bib22","first-page":"751","article-title":"Overexpression of histone deacetylase 11 suppresses basal-like breast cancer cell invasion and metastasis. Nan Fang Yi Ke Da Xue Xue Bao","volume":"39","author":"Yi","year":"2019","journal-title":"J. South. Med. Univ."},{"key":"10.1016\/j.bbrep.2026.102814_bib23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41580-026-00947-3","article-title":"Subcellular localization as a driver of protein function","volume":"27","author":"Sigaeva","year":"2026","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.bbrep.2026.102814_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1515\/mr-2024-0044","article-title":"Emerging magic bullet: subcellular organelle-targeted cancer therapy","volume":"5","author":"Yan","year":"2024","journal-title":"Medical Rev."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102814_bib25","first-page":"13","article-title":"Protein mislocalization: mechanisms, functions and clinical applications in cancer","volume":"1846","author":"Wang","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrep.2026.102814_bib26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biochi.2015.03.023","article-title":"The roles of nucleolin subcellular localization in cancer","volume":"113","author":"Berger","year":"2015","journal-title":"Biochimie"},{"key":"10.1016\/j.bbrep.2026.102814_bib27","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/febs.15456","article-title":"HDAC11 is a novel regulator of fatty acid oxidative metabolism in skeletal muscle","volume":"288","author":"Hurtado","year":"2021","journal-title":"FEBS J."},{"issue":"7","key":"10.1016\/j.bbrep.2026.102814_bib28","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1158\/0008-5472.CAN-08-3458","article-title":"Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells","volume":"69","author":"Azuma","year":"2009","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bbrep.2026.102814_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/molbev\/msag150","article-title":"Functional divergence and structural changes of class IV histone deacetylases (HDACs) across the tree of life","volume":"43","author":"Nov\u00e1kov\u00e1","year":"2026","journal-title":"Mol. Biol. Evol."},{"issue":"42","key":"10.1016\/j.bbrep.2026.102814_bib30","doi-asserted-by":"crossref","first-page":"50577","DOI":"10.1021\/acsomega.5c08195","article-title":"Substrate-Guided Development of HDAC11-Selective inhibitors featuring \u03b1-Amino amide zinc-binding groups","volume":"10","author":"Hilscher","year":"2025","journal-title":"ACS Omega"},{"issue":"6","key":"10.1016\/j.bbrep.2026.102814_bib31","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1021\/acs.jmedchem.5c03107","article-title":"Discovery of a hydroxamic acid-based HDAC11 isoform-selective inhibitor with oral Anti-AML potency","volume":"69","author":"Chai","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrep.2026.102814_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/biom9030082","article-title":"Structural determinants of isoform selectivity in PI3K inhibitors","volume":"9","author":"Miller","year":"2019","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.bbrep.2026.102814_bib33","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.bpj.2020.08.037","article-title":"Isoform-selective enzyme inhibitors by exploring pocket size according to the lock-and-key principle","volume":"119","author":"Dudutien\u0117","year":"2020","journal-title":"Biophys. J."},{"key":"10.1016\/j.bbrep.2026.102814_bib34","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/s41467-023-38039-x","article-title":"Engineering protein-based therapeutics through structural and chemical design","volume":"14","author":"Ebrahimi","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrep.2026.102814_bib35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/bjc.2011.9","article-title":"Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease","volume":"104","author":"Kang","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"18","key":"10.1016\/j.bbrep.2026.102814_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202400249","article-title":"Cell membrane as A promising therapeutic target: from materials design to biomedical applications","volume":"63","author":"Wu","year":"2024","journal-title":"Angew. Chem."},{"key":"10.1016\/j.bbrep.2026.102814_bib37","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1038\/s41467-019-10920-8","article-title":"Membrane protein-regulated networks across human cancers","volume":"10","author":"Lin","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrep.2026.102814_bib38","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41419-025-08125-7","article-title":"Development of antibody drug conjugates targeting epithelial membrane protein 2-highly expressed lung cancer","volume":"16","author":"Zheng","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102814_bib39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/ijms25010277","article-title":"FT895 impairs mitochondrial function in malignant peripheral nerve sheath tumor cells","volume":"25","author":"Huang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102814_bib40","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41420-024-02277-9","article-title":"Mitochondria-targeted antioxidant MitoQ radiosensitizes tumors by decreasing mitochondrial oxygen consumption","volume":"10","author":"Rondeau","year":"2024","journal-title":"Cell Death Discov."},{"issue":"23","key":"10.1016\/j.bbrep.2026.102814_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500203","article-title":"PROTAC-based HDAC degradation: a paradigm shift in targeted epigenetic therapies","volume":"20","author":"Himaja","year":"2025","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102814_bib42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102814_bib43","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"3","key":"10.1016\/j.bbrep.2026.102814_bib44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bbrep.2026.102814_bib45","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1535-7163.MCT-23-0747","article-title":"PROTACs: current and future potential as a precision medicine strategy to combat cancer","volume":"23","author":"Rutherford","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102814_bib46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"issue":"23","key":"10.1016\/j.bbrep.2026.102814_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400267","article-title":"Proteolysis targeting Chimeras (PROTACs) in breast cancer therapy","volume":"19","author":"Jin","year":"2024","journal-title":"ChemMedChem"},{"issue":"36","key":"10.1016\/j.bbrep.2026.102814_bib48","doi-asserted-by":"crossref","first-page":"14625","DOI":"10.1039\/D4SC03145H","article-title":"Targeted protein degradation in the mitochondrial matrix and its application to chemical control of mitochondrial morphology","volume":"15","author":"Yamada","year":"2024","journal-title":"Chem. Sci."},{"issue":"23","key":"10.1016\/j.bbrep.2026.102814_bib49","doi-asserted-by":"crossref","first-page":"12861","DOI":"10.1021\/jacs.3c03756","article-title":"Mitochondrial protease targeting chimeras for mitochondrial matrix protein degradation","volume":"145","author":"Wang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"6776","key":"10.1016\/j.bbrep.2026.102814_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/science.adx5094","article-title":"Targeted protein degradation in the transmembrane and extracellular space","volume":"390","author":"Zhu","year":"2025","journal-title":"Science (New York, N.Y.)"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102814_bib51","doi-asserted-by":"crossref","first-page":"9374","DOI":"10.1038\/s41467-025-64426-7","article-title":"Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression","volume":"16","author":"Zhou","year":"2025","journal-title":"Nat. Commun."},{"issue":"Pt 4","key":"10.1016\/j.bbrep.2026.102814_bib52","article-title":"Development of nanobody-based PROTAC (NbTAC) for ROR1 degradation by RNF149","volume":"319","author":"Zhao","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbrep.2026.102814_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115755","article-title":"Integrating PROTAC-based targeted protein degradation with nanodelivery systems to overcome cancer therapeutic resistance","volume":"229","author":"Gou","year":"2026","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580826003742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580826003742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:05:04Z","timestamp":1793973904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580826003742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":53,"alternative-id":["S2405580826003742"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2026.102814","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Membrane-associated HDAC11: A potential new therapeutic targeting compartment in cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2026.102814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102814"}}